| Q58698408 | A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis |
| Q52579654 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. |
| Q35642745 | Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo |
| Q36169814 | Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease |
| Q37407676 | Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts |
| Q57801281 | CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma |
| Q37133709 | Cancer stem cells in multiple myeloma. |
| Q38161351 | Cancer stem cells of differentiated B-cell malignancies: models and consequences |
| Q34462722 | Cancer stem cells: controversies in multiple myeloma |
| Q37398584 | Cancer stem cells: relevance to SCT |
| Q24610291 | Characterization of clonogenic multiple myeloma cells |
| Q39158457 | Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance |
| Q35849637 | Clinical implication of centrosome amplification in plasma cell neoplasm |
| Q24644883 | Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance |
| Q34418934 | Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone |
| Q30436741 | Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors |
| Q37357836 | Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines |
| Q36977712 | Extravasation and homing mechanisms in multiple myeloma |
| Q38169258 | Fact or fiction--identifying the elusive multiple myeloma stem cell |
| Q37535244 | Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. |
| Q24670135 | High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis |
| Q35194860 | High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells |
| Q35219019 | Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone |
| Q37137940 | Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma |
| Q33590627 | Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma |
| Q38228353 | Immunological dysregulation in multiple myeloma microenvironment. |
| Q35674158 | Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. |
| Q30437109 | Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. |
| Q37357828 | Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease |
| Q35070415 | Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model |
| Q27302313 | Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies |
| Q33820610 | Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications |
| Q26752365 | Multiple myeloma cancer stem cells |
| Q37029171 | Multiple myeloma cancer stem cells |
| Q39895963 | Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. |
| Q37419425 | N-cadherin impedes proliferation of the multiple myeloma cancer stem cells |
| Q36288116 | NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity |
| Q35083372 | Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system |
| Q34380431 | Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice |
| Q38395139 | Organ-on-a-chip: development and clinical prospects toward toxicity assessment with an emphasis on bone marrow |
| Q33768466 | Osteoblastogenesis and tumor growth in myeloma |
| Q28364664 | Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods |
| Q28731827 | Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma |
| Q35834665 | Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow |
| Q35824980 | Progress in myeloma stem cells |
| Q36370250 | Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. |
| Q36405908 | Stemness of B-cell progenitors in multiple myeloma bone marrow |
| Q37377754 | Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo |
| Q37859253 | The bone marrow stroma in hematological neoplasms--a guilty bystander. |
| Q37334601 | The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth |
| Q38569328 | The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell |
| Q35603152 | The immune microenvironment of myeloma |
| Q28076070 | The myeloma stem cell concept, revisited: from phenomenology to operational terms |
| Q35070420 | The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype |
| Q37034189 | The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo |
| Q33685257 | The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease |
| Q35202314 | The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma |
| Q36092153 | Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth |
| Q34020937 | Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 |
| Q43008917 | Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model |
| Q36742501 | Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth |